Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Three series of DPP-IV inhibitors prepared and tested at Boehringer Ingelheim

April 16, 2004

CS-917 completes second phase IIa trial

April 15, 2004

Sangart cleared to commence Swedish phase II trial of Hemospan

April 15, 2004

Dual PPARalpha/gamma agonists under investigation for metabolic syndromes at Dr. Reddy

April 15, 2004

Melanin-concentrating hormone receptor antagonist against obesity

April 14, 2004

Novartis to license calcitonin technology from Unigene

April 14, 2004

Ipsen enters into licensing agreement for Auxilium's Testim

April 13, 2004

Phase II study of Puricase for severe gout begins

April 13, 2004

New MTP inhibitors in early development at Janssen

April 13, 2004

New glucocorticoid receptor modulators discovered at Boehringer Ingelheim

April 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...